Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TISLELIZUMAB for Lung neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 1,119 adverse event reports in the FDA FAERS database where TISLELIZUMAB was used for Lung neoplasm malignant.

Most Reported Side Effects for TISLELIZUMAB

Side Effect Reports % Deaths Hosp.
Myelosuppression 2,142 42.9% 5 1,052
White blood cell count decreased 327 6.6% 5 151
Neutrophil count decreased 277 5.5% 4 112
Hepatic function abnormal 221 4.4% 1 144
Pruritus 213 4.3% 1 101
Rash 208 4.2% 3 89
Platelet count decreased 183 3.7% 10 101
Pyrexia 175 3.5% 3 117
Nausea 165 3.3% 5 72
Diarrhoea 145 2.9% 6 87
Liver injury 139 2.8% 2 76
Decreased appetite 133 2.7% 3 72
Off label use 130 2.6% 11 51
Asthenia 125 2.5% 0 73
Anaemia 119 2.4% 4 33

Other Indications for TISLELIZUMAB

Oesophageal carcinoma (420) Hepatic cancer (315) Gastric cancer (264) Squamous cell carcinoma of lung (246) Nasopharyngeal cancer (230) Lung adenocarcinoma (165) Hepatocellular carcinoma (131) Metastases to lymph nodes (103) Adenocarcinoma gastric (99) Neoplasm malignant (90)

Other Drugs Used for Lung neoplasm malignant

ERLOTINIB (9,207) OSIMERTINIB (4,754) NIVOLUMAB (4,197) PEMBROLIZUMAB (3,575) CARBOPLATIN (3,487) ALECTINIB (2,932) PEMETREXED (2,422) CRIZOTINIB (1,949) BEVACIZUMAB (1,810) PACLITAXEL (1,747)

Related Pages

TISLELIZUMAB Full Profile All Lung neoplasm malignant Drugs TISLELIZUMAB Demographics TISLELIZUMAB Timeline